Discover why 2025 is being dubbed the Rocky Balboa market with S&P 500's impressive post-down-day rebound. Explore past ...

Bilibili's valuation continues to be attractive and doesn't reflect current market consensus. Read why I'm upgrading my ...

Dolby Laboratories' licensing model yields high margins and steady earnings, but top-line growth remains stagnant. Learn more ...

UVXY, a leveraged ETF tied to VIX futures, can act as a potential hedge in market downturns. Read more on UVXY's construction ...

Freedom Holding Corp.'s stock dip overlooks 138% user growth from strategic investments. Click for my updated look at FHRC ...

Joby Aviation continues to progress through the certification process, although this likely won't be complete until 2026.

Discover why AMN Healthcare is a buy - undervalued below $900M cap, strong cash flow, debt reduction, and strategic moves ...

Johnson Controls trades at a premium vs. historical avg., but valuation is justified by exposure to secular growth trends and ...

Chemours rises after the Environmental Protection Agency said it has withdrawn its plan to rewrite a ban on chrysotile ...

Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors and individual stocks. Read more ...

Tilray is sitting in its best position for strong gains, maybe ever since the 2018 IPO. Click to read more on why TLRY is a ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...